About
About
Philosophy
Culture
Transparency
Leadership Team
Partners
History and Global Brand
Sustainability
Innovation
Innovation
Pipeline
Clinical Trials
Investigator Research
Educational Grants
Clinical Trial Data Privacy Policy
Medical Writing Grants
Medical Information
Early Access Policy
News
News
News Posts
Social Media Community Guidelines
Products
Investors
Careers
Contact
United States
Worldwide
HOME
News
News
Back number
Please select
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
October
Oct.29, 2024
Release
Shionogi Announces Global Phase 3 Trial Demonstrates Post-Exposure Prophylactic Use of Ensitrelvir Prevents Symptomatic COVID-19
Oct.24, 2024
Release
Receives U.S. FDA Fast Track Designation for the Novel Anti-Respiratory Syncytial Virus Drug Candidate S-337395
Oct.16, 2024
Release
IDWeek 2024: Shionogi Presents Largest Global Real-World Evidence Study of Cefiderocol Demonstrating Strong Clinical Response Rates Across Seriously Ill Patients
September
Sep.04, 2024
Release
Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentations from Its Expanding Product Portfolio at IDWeek 2024
July
Jul.18, 2024
Release
Shionogi Provides Updates on Zatolmilast, an Investigational Drug for Fragile X Syndrome, Including Recent Changes to Study Protocol to Increase Access for Participants and Families
June
Jun.24, 2024
Release
Shionogi Inc. Appoints David Benadon Senior Vice President, Chief Human Resources Officer
Jun.03, 2024
Release
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats
May
May.13, 2024
Release
Shionogi Provides Updates from SCORPIO-HR, a Global Phase 3 Study of Ensitrelvir for Non-Hospitalized Participants with COVID-19
May.10, 2024
Release
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
April
Apr.18, 2024
Release
ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
March
Mar.05, 2024
Release
Shionogi Announces Xocova® (Ensitrelvir Fumaric Acid) Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection
February
Feb.09, 2024
Release
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open
Feb.05, 2024
Release
Shionogi Strengthens Regulatory Leadership with the Appointment of Dr. Ramón Polo as Senior Vice President, Head of Regulatory Affairs